RxSight (RXST) 2024 Wells Fargo Healthcare Conference summary

Adoption and market trends

• Light Adjustable Lenses (LALs) currently represent about 10% of premium intraocular lens (IOL) implants in the US, with a long-term goal to exceed 50% market share.

• The company experienced nearly 70% growth in the first half of the year, driven by strong clinical results and the unique adjustability of its lenses.

• Practices adopting the technology can recoup the cost of the Light Delivery Device (LDD) in about six months, supporting ROI for clinics.

• The US remains the largest market, with about five million cataract procedures expected in 2024 and a premium segment growing at 6%-7% annually.

• International expansion is underway, with regulatory processes ongoing in major markets and a focus on the concentrated OUS premium IOL segment.

Financial performance and guidance

• Revenue guidance for the year was raised to $139–$140 million, reflecting a strong first half and expectations for a robust fourth quarter.

• Gross margin is guided between 68% and 70%, with long-term potential to reach 85%+ at maturity, driven by product mix.

• Operating expenses are expected to increase by $2 million, supported by a recent $107 million capital raise, providing flexibility for growth.

• The company prioritizes revenue growth and market penetration over margin management, especially for LDD sales.

• Consensus for 2025 projects 33% growth, a deceleration from 2024, with management planning to provide guidance closer to the year.

Product innovation and competitive positioning

• Over 40 PMA supplements have been filed, introducing evolutionary improvements such as ActiveShields, broader correction ranges, and the LAL+ product.

• LAL+ rollout is nearly complete, offering a broader depth of focus and addressing feedback from physicians.

• The technology enables post-surgical customization, delivering twice the rate of 20/20 vision compared to other lenses.

• The company argues its LALs already provide a depth of focus comparable to EDOF lenses, making additional labeling unnecessary.

• R&D spending focuses on incremental improvements, with the view that continuous innovation drives adoption and market penetration.